The Times Tech Podcast
Babson’s David Stein: “Succeeding where Theranos failed”
Dec 15, 2023
David Stein, CEO of Babson Diagnostics, discusses the importance of blood testing, how Babson differs from Theranos, their success, using a tiny amount of blood, fighting against the Theranos effect, and the new age of biological data.
41:24
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Babson Diagnostics aims to revolutionize blood testing by using a finger prick device, eliminating the need for larger blood samples.
- Babson's partnership with BD ensures the reliability and effectiveness of their finger prick device, making it a potential game-changer in the diagnostics industry.
Deep dives
Babson Diagnostics: Delivering on the Promises of Theranos
Babson Diagnostics is a company that is about to fulfill what Theranos promised years ago. Using a little finger prick device, Babson can perform a variety of diagnostic blood tests, eliminating the need for larger blood samples. This breakthrough innovation has been in development for over eight years and has recently received key FDA approval. The company's partnership with BD has resulted in the creation of a device that collects a small and reliable blood sample, ensuring high-quality results. Babson aims to make blood testing more accessible and less traumatic, replacing traditional vials and needles with an easier and more efficient process.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
